Literature DB >> 7490731

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds.

H Sugimoto1, Y Iimura, Y Yamanishi, K Yamatsu.   

Abstract

Following the discovery of a new series of anti-acetylcholinesterase (anti-AChE) inhibitors such as 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine (1), we reported that its rigid analogue, 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine (5), had more potent activity. We have extended the structure-activity relationship (SAR) study for the rigid analogue and found that the 2-isoindoline moiety in compound 5 can be replaced with a indanone moiety (8) without a major loss in potency. Among the indanone derivatives, 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine (13e) (E2020) (IC50 = 5.7 nM) was found to be one of the most potent anti-AChE inhibitors. Compound 13e showed a selective affinity 1250 times greater for AChE than for butyrylcholinesterase. In vivo studies demonstrated that 13e has a longer duration of action than physostigmine at a dose of 5 mg/kg (po) and produced a marked and significant increase in acetylcholine content in rat cerebral cortex. We report the synthesis, SAR, and a proposed hypothetical binding site of 13e (E2020).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490731     DOI: 10.1021/jm00024a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  Donepezil.

Authors:  H M Bryson; P Benfield
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

Review 4.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 5.  The cholinergic hypothesis of Alzheimer's disease: a review of progress.

Authors:  P T Francis; A M Palmer; M Snape; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

6.  Design, Synthesis, and Evaluation of Donepezil-Like Compounds as AChE and BACE-1 Inhibitors.

Authors:  Paola Costanzo; Luca Cariati; Doriana Desiderio; Roberta Sgammato; Anna Lamberti; Rosaria Arcone; Raffaele Salerno; Monica Nardi; Mariorosario Masullo; Manuela Oliverio
Journal:  ACS Med Chem Lett       Date:  2016-03-28       Impact factor: 4.345

7.  Conformational analysis and parallel QM/MM X-ray refinement of protein bound anti-Alzheimer drug donepezil.

Authors:  Zheng Fu; Xue Li; Yipu Miao; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2013-02-18       Impact factor: 6.006

8.  The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits.

Authors:  Takayoshi Masuoka; Chiaki Kamei
Journal:  Psychopharmacology (Berl)       Date:  2009-07-29       Impact factor: 4.530

Review 9.  Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

Authors:  Nazem Bassil; George T Grossberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  New therapeutic approaches and novel alternatives for organophosphate toxicity.

Authors:  Francine S Katz; Stevan Pecic; Laura Schneider; Zhengxiang Zhu; Ashley Hastings; Michal Luzac; Joanne Macdonald; Donald W Landry; Milan N Stojanovic
Journal:  Toxicol Lett       Date:  2018-03-31       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.